Having established the allele-specific role of KrasG12D in facilitating tumor initiation and uncovering its increased activation of the PI3K-AKT-mTOR pathway compared to KrasG12C, we next sought to explore differences between KRASG12C and KRASG12D in advanced disease to determine if growth characteristics and signaling differences are maintained during tumor evolution (Fig. 3A). Here, MTOR is linked to neoplasm.